Enzalutamide-resistant LNCaP ARF877L Mutation KI model
We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model.
Check out our comprehensive platform of drug-resistant animal models
Enzalutamide-resistant LNCAP AR F877L mutant KI model
Related Content
NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer...
VIEW RESOURCEA new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum. As the discovery pipeline widens...
VIEW RESOURCE